We are pleased to share a special nutrition program to help the pancreatic cancer community during the holidays. Learn more.
PANCREATIC CANCER ACTION NETWORK BLOG
We are excited to have received Celgene’s 2014 Innovative Impact Award for our Know Your Tumor initiative, which is under development. More information will be shared when the program is widely available. Learn more.
The Pancreatic Cancer Action Network will award $4.1 million in research funding through its 2015 Grants Program. Applications are now being accepted for most grants. Learn more.
CLINICAL TRIAL NEWS: MM-398 combined with standard chemotherapy boosts overall survival by nearly 2 months in patients previously treated with gemcitabine. Learn more.
Sixteen grants totaling more than $5.1 million have been awarded to scientists and clinicians across the country this year. Learn more.
A MULTI-STEP APPROACH TO DIAGNOSING PANCREATIC CANCER EARLIER
One of the reasons that pancreatic cancer is such a challenging disease is that it is frequently diagnosed once it’s reached more advanced, aggressive stages. The best opportunity for a positive outcome is when pancreatic cancer is diagnosed early, when the patient might be eligible for surgery.
For every $1 invested by Pancreatic Cancer Action Network between 2003-2011, our research grant recipients have gone on to receive $9.93 in subsequent funding to support their pancreatic cancer studies.
Every grant recipient during that time has authored an average of 13 pancreatic cancer-related papers published in biomedical journals, and every paper has been read, built upon, and cited by other scientists an average of nearly eight times in other articles.
DECEMBER 21, 2012
FOR IMMEDIATE RELEASE
THE RECALCITRANT CANCER RESEARCH ACT, FORMERLY KNOWN AS THE PANCREATIC CANCER RESEARCH & EDUCATION ACT, Passes Congress
The Pancreatic Cancer Action Network Urges President Obama to Sign the Legislation into Law
Manhattan Beach, CA (December 21, 2012) — The Recalcitrant Cancer Research Act, formerly known as the Pancreatic Cancer Research & Education Act, has passed Congress today as part of the National Defense Authorization Act and will now be sent to President Obama to sign into law. The legislation requires the National Cancer Institute (NCI) to evaluate its current efforts in studying pancreatic cancer, lung cancer, and other recalcitrant cancers, and focus on ways to improve outcomes.
November 9, 2012
FOR IMMEDIATE RELEASE
STUDY SHOWS ABRAXANE® EXTENDS SURVIVAL FOR PATIENTS WITH ADVANCED PANCREATIC CANCER
MANHATTAN BEACH, CA (November 9, 2012) — The Pancreatic Cancer Action Network is pleased to announce Abraxane® extends survival for patients with advanced pancreatic cancer. According to Celgene Corporation, Abraxane in combination with gemcitabine when given to advanced pancreatic cancer patients who had not received previous treatment demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. Read More